Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab

Introduction: Checkpoint inhibitors, including the CTLA-4 blocking antibody ipilimumab, have become the new standard therapy for many metastatic cancers. Development of anti-drug antibodies (ADAs) after treatment with other biopharmaceuticals has been thoroughly described, but the induction of ADAs...

Descripción completa

Detalles Bibliográficos
Autores principales: Kverneland, Anders H., Enevold, Christian, Donia, Marco, Bastholt, Lars, Svane, Inge Marie, Nielsen, Claus H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927482/
https://www.ncbi.nlm.nih.gov/pubmed/29721387
http://dx.doi.org/10.1080/2162402X.2018.1424674

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927482/
https://www.ncbi.nlm.nih.gov/pubmed/29721387
http://dx.doi.org/10.1080/2162402X.2018.1424674

Ejemplares similares